Gilead Sciences licenses Xilio Therapeutics' Phase 1 tumor-activated IL-12 program, XTX301.
Gilead Sciences and Xilio Therapeutics announce an exclusive license agreement for Xilio's Phase 1 tumor-activated IL-12 program, XTX301. Xilio is a clinical-stage biotech developing tumor-activated immuno-oncology therapies, and XTX301 is currently in a Phase 1 dose escalation trial for advanced solid tumors. Gilead's clinical development program in difficult-to-treat cancers complements Xilio's platform.
March 28, 2024
4 Articles